• Legal Era India
  • Legal Era Global
  • Membership
  • Sign inSUBSCRIBE
Legal Era
X
Sign in
  • Home
  • News
    +
    • From the Courts
    • Policy & Law
    • Supreme Court (India)
    • High Court (India)
    • TAX Updates
    • MARKET WATCH
    • Deal Street
    • Global Insights
    • IBC Cases
    • Hires & Moves
    • IP News
    • Competition Verdict
    • Global Articles
    • Global Deals
  • Articles
    +
    • ABOUT THE LAW
    • AWARDS & ACCOLADES
    • Aerospace
    • Agriculture
    • Alternate Dispute Resolution
    • Banking and Finance
    • Bankruptcy
    • Book Review
    • Bribery & Corruption
    • Commercial Litigation
    • Competition Law
    • Conference Reports
    • Consumer Products
    • Contract
    • Corporate Governance
    • Corporate Law
    • Covid-19
    • Cryptocurrency
    • Cybersecurity
    • Data Protection
    • Defence
    • Digital Economy
    • E-commerce
    • Employment Law
    • Energy and Natural Resources
    • Entertainment and Sports Law
    • Environmental Law
    • FDI
    • Food and Beverage
    • Health Care
    • IBC Diaries
    • Insurance Law
    • Intellectual Property
    • International Law
    • Labour Laws
    • Litigation
    • Litigation Funding
    • Manufacturing
    • Mergers & Acquisitions
    • NFTs
    • Privacy
    • Private Equity
    • Project Finance
    • Real Estate
    • Risk and Compliance
    • Technology Media and Telecom
    • Tributes
    • Zoom In
    • Take On Board
    • In Focus
    • Law & Policy and Regulation
    • IP & Tech Era
    • Viewpoint
    • Arbitration & Mediation
    • Tax
    • Student Corner
    • ESG
    • Gaming
    • Inclusion & Diversity
  • Law Firms
    +
    • Global Law Firm
    • Asia Law Firm
    • India Law Firm
  • In-House
  • Rankings
  • E-Magazine
  • Legal Era TV
  • Legal Era TV
  • Events
  • News
    • From the Courts
    • Policy & Law
    • Supreme Court (India)
    • High Court (India)
    • TAX Updates
    • MARKET WATCH
    • Deal Street
    • Global Insights
    • IBC Cases
    • Hires & Moves
    • IP News
    • Competition Verdict
    • Global Articles
    • Global Deals
  • Articles
    • ABOUT THE LAW
    • AWARDS & ACCOLADES
    • Aerospace
    • Agriculture
    • Alternate Dispute Resolution
    • Banking and Finance
    • Bankruptcy
    • Book Review
    • Bribery & Corruption
    • Commercial Litigation
    • Competition Law
    • Conference Reports
    • Consumer Products
    • Contract
    • Corporate Governance
    • Corporate Law
    • Covid-19
    • Cryptocurrency
    • Cybersecurity
    • Data Protection
    • Defence
    • Digital Economy
    • E-commerce
    • Employment Law
    • Energy and Natural Resources
    • Entertainment and Sports Law
    • Environmental Law
    • FDI
    • Food and Beverage
    • Health Care
    • IBC Diaries
    • Insurance Law
    • Intellectual Property
    • International Law
    • Labour Laws
    • Litigation
    • Litigation Funding
    • Manufacturing
    • Mergers & Acquisitions
    • NFTs
    • Privacy
    • Private Equity
    • Project Finance
    • Real Estate
    • Risk and Compliance
    • Technology Media and Telecom
    • Tributes
    • Zoom In
    • Take On Board
    • In Focus
    • Law & Policy and Regulation
    • IP & Tech Era
    • Viewpoint
    • Arbitration & Mediation
    • Tax
    • Student Corner
    • ESG
    • Gaming
    • Inclusion & Diversity
  • Law Firms
    • Global Law Firm
    • Asia Law Firm
    • India Law Firm
  • In-House
  • Rankings
  • E-Magazine
  • Legal Era TV
  • Legal Era TV
  • Events
search-icon

Top Stories

Indonesias patent office brings with its new patent examination guidelines
HomeNewsIP News
IP News

Indonesia's patent office brings with its new patent examination guidelines

By Legal Era
25 May 2021 8:30 AM GMT

Indonesia's patent office brings with its new patent examination guidelines

Indonesias patent office brings with its new patent examination guidelines

Indonesia's patent office brings with its new patent examination guidelines Indonesia's Patent Office publishes its new patent examination guidelines. The examination guidelines bring some of the changes in the procedural requirement for new use claims. Article 4(f) of the Indonesian Patent Law says that any such new use of a known or existing product is not patentable. Contrary to this,...

ToRead the Full Story, Subscribe to Legal Era

Access the exclusive LEGAL ERAStories,Editorial and Expert Opinion

Subscribe Now
AlreadyaSubscriber?SigninNow
View Plans

Indonesia's patent office brings with its new patent examination guidelines

Indonesia's Patent Office publishes its new patent examination guidelines. The examination guidelines bring some of the changes in the procedural requirement for new use claims.

Article 4(f) of the Indonesian Patent Law says that any such new use of a known or existing product is not patentable. Contrary to this, the guidelines allow patentability of second medical use as long as the claim is written using the purpose limited product claim or EPC2000 format.

A claim by using the compound mechanism will be considered too broad and for this the guidelines states for identifying the particular disease. For claims supporting the new use and/or increased efficiency claims, the new use must include clinical experimental data, animal experimental data either in vivo or in vitro, data indicating decreased side effects, and other relevant information which supports the efficiency.

As per the guidelines, if in case the feature of use, activity, or function serves the distinguishing feature, in this case, the second medical use claim will also be patentable. These guidelines try to provide a wider scope of the patentable subject matter. These guidelines seem to be more favorable to pharmaceuticals companies.

Commenting on the same, Kin Wah Chow, a registered foreign lawyer said, "Based on briefings to practitioners, the Directorate General of Intellectual Property (DGIP) is trying to take a pragmatic approach - still allowing medical use of a known substance to be patented where there is no earlier medical use for that substance. The DGIP is considering the importance of protecting investment in discovering and proving new medical use demonstrated in the current pandemic climate. We hope that the bar against patenting second medical use will be removed,"

Next Story
TAGS:
  • #Indonesia
  • #Patent
  • #New use claims
  • #Patentability
  • #Pharmaceuticals
  • #Efficiency
  • #Examination guidelines
Similar Posts
Trending Now
Recommended Articles
  • News
  • From the Courts
  • Supreme Court (India)
  • High Court (India)
  • Global Insights
  • Deal Street
  • Hires & Moves
  • Refund & Cancellation Policy
  • Articles
  • Zoom In
  • Take On Board
  • In Focus
  • Law & Policy
  • IP & Tech Era
  • Viewpoint
  • Arbitration & Mediation
  • Tax
  • Student Corner
  • Interviews
  • Law Firms
  • E-Magazine
  • Legal Era TV
  • Membership
  • Reader's Feedback
  • Cartoons
  • Subscribe
  • Advertise
Follow Us
Subscribe Newsletter
  • 2023© All rights reserved Legal Era Media Group
  • Who We Are
  • Careers
  • Advertise with Us
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
Powered by  Hocalwire
X
X